QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 harvard-bioscience-granted-180-days-or-until-march-30-2026-by-nasdaq-for-compliance

- SEC Filing

 benchmark-maintains-speculative-buy-on-harvard-bioscience-lowers-price-target-to-2

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price ta...

 harvard-bioscience-enters-sixth-amendment-to-credit-agreement-lenders-agree-not-to-test-financial-covenants-for-q3-2025-agrees-to-pay-400k-fees-to-lenders-explores-alternative-capital-sources-for-refinancing-says-there-is-substantial-doubt-about-cos-ability-to-continue-as-a-going-concern

Item 1.01. Entry into a Material Definitive Agreement. On August 8, 2025, Harvard Bioscience, Inc. (the "Company") ente...

 harvard-bioscience-sees-q3-sales-19000m-21000m-vs-2175m-est

Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $19.000 million-$21.000 million vs $21.75 million analyst estimate.

 harvard-bioscience-q2-adj-eps-001-inline-sales-2045m-beat-2040m-estimate

Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The ...

 benchmark-maintains-speculative-buy-on-harvard-bioscience-lowers-price-target-to-3

Benchmark analyst Bruce Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price targe...

 harvard-bioscience-sees-q2-sales-18000m-20000m-vs-1920m-est

Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $18.000 million-$20.000 million vs $19.20 million analyst estimate.

 harvard-bioscience-q1-adj-eps-001-beats-004-estimate-sales-2177m-beat-1920m-estimate

Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION